Ceapro Inc V.CZO

AEZS Q4

[lscfa]

https://www.globenewswire.com/news-release/2024/03/27/2853131/0/en/Aeterna-Zentaris-Reports-Fourth-Quarter-and-Full-Year-2023-Financial-Results-and-Announces-Completion-of-Enrollment-in-Ongoing-Pivotal-DETECT-Trial-for-the-Diagnosis-of-Childhood-O.html

[prophetoffactz]

"Dr. Klaus Paulini, Chief Executive Officer of Aeterna commented, “With enrollment now completed in the DETECT-trial, we expect the completion of the DETECT-trial in the second quarter and Top-Line Data in the third quarter of this year." news release That sets up a potential North American diagnostic deal. Strongbridge's upfront payment, adjusted for inflation, was ~C$40 million

[lscfa]

A crummy $66,000 US in sales of products to European partner in Q4.

[prophetoffactz]

The analyst didn't have anything forcast for revenue in Q4. The estimate climbs to $1.1 million in Q1. Aeterna Zentaris Inc. (AEZS) Analyst Ratings, Estimates & Forecasts - Yahoo Finance This is a pediatric test in many markets. In the US it can also qualify for orphan pricing. If AEZS can establish its test as a standalone test it could be a game-changer. The pediatric trial is set up

[Hopeforthebest]

Gagnon should once again remind Czo shareholders why it is a benifit for shareholders to merger with Aezs. It is clearly evident that Aezs did not want the 2023 4th qrtr and yearend report to go out before the vote as the results are absolutely PATHETIC with zero hope of improvement in the near future. AEZS is bleeding money and will soon add Czo to the wounded fold.  I also wonder what the

[boazklinghorn]

My god reading the annual results for Atartis Zentrapia are making those 900K bid at 23 look pretty tempting

[boazklinghorn]

That said CZO stock is valued as function of the AEZS price now. At 2.72 your CZO is objectively worth 25.6 cents at this moment.